Federal/JJ drug/NN regulators/NNS ,/, concerned/VBN over/IN British/JJ reports/NNS that/IN diabetics/NNS have/VBP died/VBN after/IN shifting/VBG from/IN animal/JJ to/TO human-based/JJ insulin/NN ,/, say/VBP they/PRP are/VBP considering/VBG a/DT study/NN to/TO see/VB if/IN similar/JJ deaths/NNS have/VB occurred/VBN here/RB ./.
The/DT United/NNP Kingdom/NNP reports/NNS came/VBD from/IN Dr./NNP Patrick/NNP Toseland/NNP ,/, head/NN of/IN clinical/JJ chemistry/NN at/IN Guy/NNP 's/POS Hospital/NNP in/IN London/NNP ./.
In/IN a/DT telephone/NN interview/NN Friday/NNP ,/, Dr./NNP Toseland/NNP said/VBD the/DT number/NN of/IN sudden/JJ ,/, unexplained/JJ deaths/NNS of/IN diabetics/NNS he/PRP had/VBD seen/VBN this/DT year/NN was/VBD #/CD compared/VBN with/IN just/RB two/CD in/IN #/CD ./.
At/IN least/JJS six/CD of/IN the/DT deaths/NNS occurred/VBD among/IN relatively/RB young/JJ diabetics/NNS who/WP had/VBD switched/VBN from/IN animal/NN to/TO human/JJ insulin/NN within/IN the/DT past/JJ year/NN ,/, he/PRP said/VBD ./.
Dr./NNP Solomon/NNP Sobel/NNP ,/, director/NN of/IN metabolism/NN and/CC endrocrine/JJ drug/NN products/NNS for/IN the/DT U.S./NNP Food/NNP and/CC Drug/NNP Administration/NNP ,/, said/VBD FDA/NNP officials/NNS have/VBP discussed/VBN Dr./NNP Toseland/NNP 's/POS findings/NNS ``/`` fairly/RB intensively/RB ./. ''/''
While/IN there/EX have/VBP been/VBN no/DT reports/NNS of/IN similar/JJ sudden/JJ unexplained/JJ deaths/NNS among/IN diabetics/NNS in/IN the/DT U.S./NNP ,/, Dr./NNP Sobel/NNP said/VBD the/DT FDA/NNP plans/NNS to/TO examine/VB Dr./NNP Toseland/NNP 's/POS evidence/NN and/CC is/VBZ considering/VBG its/PRP$ own/JJ study/NN here/RB ./.
Dr./NNP Toseland/NNP ,/, a/DT toxicologist/NN ,/, said/VBD he/PRP was/VBD preparing/VBG an/DT article/NN for/IN a/DT British/JJ forensic/JJ medical/JJ journal/NN raising/VBG the/DT possibility/NN that/IN the/DT deaths/NNS may/MD have/VB occurred/VBN after/IN human/JJ insulin/NN blunted/VBD critical/JJ warning/NN signs/NNS indicating/VBG hypoglycemia/NN ,/, or/CC low/JJ blood/NN sugar/NN ,/, which/WDT can/MD kill/VB diabetics/NNS ./.
The/DT usual/JJ warning/NN signs/NNS of/IN hypoglycemia/NN include/VBP sweating/NN ,/, anxiety/NN and/CC cramps/NNS ./.
With/IN proper/JJ warning/NN ,/, diabetics/NNS can/MD easily/RB raise/VB their/PRP$ blood/NN sugar/NN to/TO safe/JJ levels/NNS by/IN eating/VBG sugar/NN or/CC sugary/JJ food/NN ./.
``/`` The/DT anecdotal/JJ data/NN certainly/RB shows/VBZ that/IN some/DT of/IN the/DT people/NNS were/VBD not/RB aware/JJ of/IN the/DT rapid/JJ onset/NN of/IN hypoglycemia/NN ,/, ''/'' Dr./NNP Toseland/NNP said/VBD ./.
At/IN the/DT U.S./NNP National/NNP Institutes/NNP of/IN Health/NNP ,/, Dr./NNP Robert/NNP E./NNP Silverman/NNP ,/, chief/NN of/IN the/DT diabetes/NN program/NN branch/NN ,/, said/VBD no/DT evidence/NN of/IN unexpected/JJ deaths/NNS from/IN hypoglycemia/NN had/VBD shown/VBN up/RP in/IN a/DT study/NN of/IN #,#/CD diabetics/NNS that/WDT has/VBZ been/VBN under/IN way/NN at/IN NIH/NNP for/IN five/CD years/NNS ./.
However/RB ,/, he/PRP said/VBD officials/NNS conducting/VBG the/DT study/NN had/VBD n't/RB been/VBN looking/VBG for/IN signs/NNS of/IN problems/NNS related/VBN to/TO hypoglycemia/NN unawareness/NN ./.
``/`` We/PRP are/VBP now/RB monitoring/VBG for/IN it/PRP much/RB more/RBR closely/RB ,/, ''/'' he/PRP said/VBD ./.
``/`` We/PRP do/VBP know/VB there/EX are/VBP slight/JJ differences/NNS in/IN the/DT way/NN human/JJ and/CC animal/JJ insulins/NNS drive/VBP down/RP blood/NN sugar/NN ,/, ''/'' Dr./NNP Sobel/NNP said/VBD ./.
The/DT human-based/JJ drug/NN starts/VBZ the/DT blood/NN sugar/NN dropping/VBG sooner/RBR and/CC drives/VBZ it/PRP down/RP faster/RBR ,/, he/PRP said/VBD ./.
``/`` But/CC we/PRP do/VBP n't/RB believe/VB there/EX is/VBZ enough/JJ of/IN a/DT difference/NN to/TO be/VB clinically/RB significant/JJ ,/, ''/'' Dr./NNP Sobel/NNP said/VBD ./.
Reports/NNS of/IN Dr./NNP Toseland/NNP 's/POS findings/NNS in/IN the/DT British/JJ press/NN have/VBP triggered/VBN widespread/JJ concern/NN among/IN diabetics/NNS there/RB ./.
Both/DT the/DT British/NNP Diabetic/NNP Association/NNP and/CC the/DT Committee/NNP on/IN Safety/NNP in/IN Medicines/NNP --/: Britain/NNP 's/POS equivalent/NN of/IN the/DT U.S./NNP FDA/NNP --/: recently/RB issued/VBD statements/NNS noting/VBG the/DT lack/NN of/IN hard/JJ scientific/JJ evidence/NN to/TO support/VB Dr./NNP Toseland/NNP 's/POS findings/NNS ./.
On/IN Friday/NNP ,/, the/DT American/NNP Diabetes/NNP Association/NNP issued/VBD a/DT similar/JJ statement/NN urging/VBG the/DT six/CD million/CD U.S./NNP diabetics/NNS not/RB to/TO overreact/VB to/TO the/DT British/JJ report/NN ./.
``/`` A/DT loss/NN of/IN the/DT warning/NN symptoms/NNS of/IN hypoglycemia/NN is/VBZ a/DT complex/JJ problem/NN that/WDT is/VBZ very/RB unlikely/JJ to/TO be/VB due/RB simply/RB to/TO the/DT type/NN of/IN insulin/NN used/VBN ,/, ''/'' the/DT American/JJ association/NN said/VBD ./.
The/DT FDA/NNP already/RB requires/VBZ drug/NN manufacturers/NNS to/TO include/VB warnings/NNS with/IN insulin/NN products/NNS that/IN symptoms/NNS of/IN hypoglycemia/NN are/VBP less/RBR pronounced/JJ with/IN human/JJ insulin/NN than/IN with/IN animal-based/JJ products/NNS ./.
Eli/NNP Lilly/NNP &/CC Co./NNP ,/, the/DT Indianapolis-based/JJ drug/NN manufacturer/NN ,/, dominates/VBZ the/DT U.S./NNP human/JJ insulin/NN market/NN with/IN its/PRP$ product/NN known/VBN as/IN Humulin/NNP ./.
Lilly/NNP is/VBZ building/VBG plants/NNS to/TO make/VB the/DT insulin/NN in/IN Indianapolis/NNP and/CC Fagershein/NNP ,/, France/NNP ./.
In/IN its/PRP$ latest/JJS annual/JJ report/NN ,/, Lilly/NNP said/VBD Humulin/NNP sales/NNS have/VBP shown/VBN ``/`` excellent/JJ growth/NN ./. ''/''
Lilly/NNP officials/NNS said/VBD they/PRP had/VBD seen/VBN reports/NNS of/IN hypoglycemic/JJ unawareness/NN among/IN some/DT patients/NNS making/VBG the/DT shift/NN from/IN animal/JJ to/TO human/JJ insulin/NN ,/, but/CC did/VBD n't/RB know/VB if/IN the/DT problem/NN had/VBD caused/VBN any/DT deaths/NNS ./.
Dr./NNP Leigh/NNP Thompson/NNP ,/, a/DT Lilly/NNP group/NN vice/NN president/NN ,/, said/VBD the/DT company/NN 's/POS clinical/JJ trials/NNS of/IN both/CC its/PRP$ animal/JJ and/CC human-based/JJ insulins/NNS indicated/VBD no/DT difference/NN in/IN the/DT level/NN of/IN hypoglycemia/NN between/IN users/NNS of/IN either/DT product/NN ./.
Dr./NNP Toseland/NNP said/VBD most/JJS of/IN the/DT British/JJ diabetics/NNS who/WP died/VBD had/VBD been/VBN taking/VBG a/DT human-based/JJ insulin/NN made/VBN by/IN Novo$$Nordisk/NNP ,/, a/DT Danish/JJ manufacturer/NN ./.
None/NN of/IN the/DT diabetics/NNS were/VBD using/VBG Lilly/NNP 's/POS insulin/NN ./.
